Chemical Nameelexacaftor, ivacaftor, and tezacaftor
Dosage FormTablet (oral; 100 mg elexacaftor, 50 mg tezacaftor, and 75 mg ivacaftor, co-packaged with 150 mg ivacaftor)
Drug ClassCFTR potentiators
CompanyVertex Pharms Inc
Approval Year2019


  • Trikafta is indicated for the treatment of cystic fibrosis (CF) in patients aged 12 years and older who have at least one F508del mutation in the CFTR gene. If the patient’s genotype is unknown, an FDA-cleared CF mutation test should be used to confirm the presence of at least one F508del mutation.
Last updated on 6/11/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Trikafta (elexacaftor, ivacaftor, and tezacaftor) Prescribing Information2020Vertex Pharmaceuticals